LAIR1 and neoplasm: Currently, a dimeric LAIR-2 Fc fusion protein, NC410, which both targets the tumor ECM and promotes T-cell function through blockade of LAIR-1-mediated inhibition, is being tested in a trial as cancer immunotherapy72.